PerkinElmer
check quantity

Membrane Target Systems: Melatonin MT2 (human) membrane preparation, in CHO-K1 cells. 400 Units.

Cell membranes expressing recombinant human melatonin MT2 receptor, for ligand binding assays. Our Membrane Target System membranes are prepared from cells that express recombinant or endogenous receptors. Selected for optimal performance in binding assays.

Some of our receptors may be restricted for sale in specified countries. Please inquire.

Part Number
List Price
Your Price
Quantity
ES-621-M400UA
1800.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Membrane Target Systems are quality assured frozen membranes from cells that express recombinant or endogenous receptors. We submit every batch of receptor to stringent quality control testing that includes saturation radioligand binding assay to determine receptor concentration (Bmax) and affinity (Kd). Competition binding assays are performed determine affinity (Ki) against known reference agonists and antagonists. GTPgS data is also provided for some of our Gi coupled receptors.

Membranes are carefully prepared and ready for a variety of HTS applications, including radioligand binding (using either proximity methods, such as FlashPlate, or classical filtration methods).

Products are packaged as frozen crude membrane preparations. One assay unit is defined as micrograms of protein, defined by competition binding assay (filtration). A complete product description and recommended protocol are included on the Product Information Sheet (see Certificate of Analysis).

Specifications

Assay Target Class GPCR
Assay Target Type Membrane preparation
Assay Validated Binding
Host Cell CHO-K1
Product Brand Name Membrane Target Systems
Receptor Type Melatonin
Shipping Condition Dry Ice
Unit Size 400 units
Resources, Events & More
  • All

Brochure

GPCRs: The Pathway to Discovery

G protein coupled-receptors (GPCRs) are one of the most intensively studied drug targets, with up to one-third of all marketed therapeutics acting by binding to GPCRs. Therapies that target GPCRs include both agonist and antagonists that are used in the treatment of disease in nearly every major organ system and hold significance in several therapeutic areas, such as cardiovascular diseases, neurosciences, respiratory diseases, metabolic disorders, oncology, and rare diseases.

We know the importance of furthering GPCR research - and we answer the call with application notes, white papers, and end-to-end solutions including reagents, instruments, and tools for all aspects of research into today’s most promising drug target.

PDF 1 MB